sensit
specif
b
r
c
pandem
influenza
outbreak
result
death
countri
taiwan
influenza
rapid
test
vitro
diagnost
devic
fluivd
requir
document
review
market
approv
taiwan
food
drug
administr
purpos
studi
investig
analyt
sensit
specif
fluivd
use
taiwan
analyt
sensit
specif
test
perform
influenza
antigen
viru
viru
b
viru
human
coronaviru
total
seven
domest
import
fluivd
sampl
collect
sampl
inadequ
label
includ
remov
packag
insert
incorrect
insert
inform
analyt
sensit
fluivd
flu
b
ngml
ngml
ngml
respect
cell
cultur
infect
dose
ccid
label
averag
sensit
fluivd
log
ae
log
ae
ccid
ml
respect
specif
test
product
crossreact
human
coronaviru
studi
provid
import
inform
fluivd
regul
statu
thu
help
govern
formul
polici
regul
vitro
diagnost
devic
taiwan
triplereassort
swine
influenza
viru
human
swine
avian
genom
identifi
usa
ten
year
later
human
found
infect
influenza
virus
novel
human
influenza
viru
caus
worldwid
respiratori
diseas
outbreak
april
major
transmiss
rout
influenza
viru
via
respiratori
droplet
releas
cough
influenza
viru
replic
epitheli
cell
upper
respiratori
tract
destroy
host
cell
spread
infect
cell
clinic
manifest
influenza
fever
headach
myalgia
fatigu
rhinorrhea
sore
throat
cough
impact
influenza
outbreak
much
higher
children
adult
healthi
adult
recov
day
influenza
predomin
serotyp
season
wherea
viru
still
cocircul
influenza
b
strain
pandem
influenza
outbreak
result
death
countri
convent
diagnost
test
influenza
viru
includ
viru
incub
nucleic
acid
amplif
test
viru
incub
first
method
use
diagnos
viru
infect
take
day
amplifi
viru
host
cell
nucleic
acid
amplif
test
sensit
method
detect
viru
infect
pretreat
sampl
includ
viru
isol
nucleic
extract
still
requir
day
method
suitabl
rapid
screen
influenza
viru
vitro
diagnost
devic
ivd
play
crucial
role
diseas
diagnosi
rapid
conveni
properti
diagnost
accuraci
ivd
depend
sensit
specif
previou
studi
evalu
rapid
detect
test
respiratori
syncyti
viru
found
sensit
specif
devic
respect
april
studi
conduct
iregbu
et
al
perform
dual
path
platform
test
kit
reveal
sensit
specif
contrast
studi
shrivastava
et
al
report
commerci
dengu
antigen
kit
sensit
clinic
sampl
studi
report
sensit
influenza
ivd
fluivd
detect
influenza
previou
studi
use
four
commerci
rapid
test
kit
fluivd
rapid
test
kit
base
immunochromatograph
test
type
ivd
design
easi
fast
oper
enabl
physician
obtain
result
primari
influenza
screen
site
fluivd
rapid
test
kit
classifi
lowrisk
class
devic
accord
medic
devic
regul
risk
assess
taiwan
appli
approv
taiwan
food
drug
administr
fda
premarket
approv
via
fast
tract
pathway
exempt
substanti
perform
review
studi
collect
taiwanfdaapprov
fluivd
taiwanes
market
evalu
perform
standard
antigen
prepar
viral
cultur
purifi
hemagglutinin
use
evalu
analyt
sensit
specif
fluivd
result
repres
actual
respons
rapid
test
kit
provid
refer
futur
amend
regul
fluivd
purchas
directli
manufactur
local
distributor
differ
lot
product
name
lot
number
manufactur
countri
fluivd
list
tabl
appear
product
label
fluivd
compar
inform
licens
includ
chines
english
name
licens
number
name
manufactur
address
manufactur
expir
date
sensit
assay
describ
previous
modif
sensit
collect
fluivd
specifi
ha
concentr
ccid
ha
standard
consist
influenza
antigen
dilut
individu
ngml
ngml
ngml
respect
dilut
buffer
provid
fluivd
addit
influenza
virus
prepar
infect
rhabdomyosarcoma
rd
cell
dilut
concentr
ccid
ml
ccid
ml
respect
minimum
essenti
medium
gibco
grand
island
ny
usa
sensit
assay
fluivd
includ
posit
neg
control
carri
follow
instruct
j
u
r
n
l
f
f
n
r
u
g
n
l
oper
manual
two
independ
welltrain
technician
perform
experi
prepar
infect
cell
extract
contain
ccid
ml
viru
use
evalu
specif
fluivd
experiment
protocol
carri
accord
oper
manual
fluivd
two
independ
welltrain
research
carri
experi
fluivd
classifi
class
medic
devic
indic
licens
could
easili
obtain
document
review
therefor
qualiti
fluivd
need
investig
monitor
taiwan
suspect
influenza
patient
immedi
test
fluivd
primari
screen
site
epidem
area
therapeut
strategi
divid
two
part
base
test
result
test
result
posit
patient
exhibit
influenzalik
symptom
patient
immedi
administ
antivir
drug
osletamivir
tamiflu
continu
monitor
flu
pcr
test
kit
howev
neg
test
result
indic
patient
common
cold
antivir
drug
treatment
given
use
fluivd
play
crucial
role
control
influenza
epidem
henc
falseposit
outcom
may
caus
inappropri
administr
osletamivir
could
lead
futur
challeng
prevent
influenza
prior
sever
commerci
fluivd
rapid
test
kit
approv
taiwan
howev
influenza
pandem
taiwan
fda
issu
mani
licens
similar
product
thu
aim
examin
analyt
sensit
specif
flu
aivd
use
taiwan
total
product
fluivd
licens
collect
seven
domest
import
fluivd
product
label
sampl
compli
regul
taiwan
fda
exampl
unsatisfactori
product
label
lack
product
name
andor
licens
number
packag
buffer
contain
product
packag
insert
packag
insert
indic
sensit
product
percentag
unsatisfactori
product
label
domest
import
kit
respect
base
reaction
principl
detect
target
collect
sampl
group
ha
viral
particl
fluivd
belong
ha
group
evalu
analyt
sensit
world
health
organ
intern
standard
influenza
antigen
shown
tabl
seven
product
three
fluivd
licens
aec
manufactur
usa
spain
use
ha
concentr
sensit
label
analyt
sensit
fluivd
flu
b
ngml
ngml
ngml
respect
detect
product
j
u
r
n
l
f
f
n
r
u
g
n
l
b
display
higher
analyt
sensit
product
c
sensit
result
flu
b
ident
sampl
obtain
seven
product
three
domest
fluivd
def
product
eight
fluivd
gen
import
china
uk
finland
singapor
usa
korea
ccid
label
past
year
type
type
two
main
strain
influenza
outbreak
taiwan
henc
two
viru
strain
use
influenza
viral
particl
standard
ccid
test
averag
sensit
log
ae
ccid
ml
log
ae
ccid
ml
respect
fig
unbroken
broken
dot
line
repres
mean
mean
ae
standard
deviat
sd
mean
ae
sd
sensit
test
respect
sensit
product
within
mean
ae
sd
fig
sensit
howev
product
e
l
fell
mean
ae
sd
rang
fig
seven
product
five
import
fluivd
test
sensit
label
therefor
ha
concentr
use
determin
sensit
tabl
sensit
seven
sampl
flu
b
ngml
ngml
ngml
respect
previou
research
use
clinic
specimen
monitor
clinic
perform
fluivd
studi
drexler
et
al
found
binaxnow
influenza
b
rapid
test
kit
poor
clinic
sensit
sensit
pandem
viru
posit
case
polymerasechainreactionconfirm
case
studi
uyeki
et
al
also
show
quickvu
influenza
b
test
low
sensit
detect
influenza
b
virus
center
diseas
control
prevent
screen
specimen
posit
result
novel
influenza
use
directigen
ez
flu
b
obtain
sensit
assum
one
reason
discrep
human
epidem
strain
influenza
virus
use
fluivd
match
current
influenza
viru
outbreak
strain
pandem
influenza
viru
strain
vari
year
year
countri
countri
exampl
influenza
strain
use
master
influenza
viru
strain
develop
monoclon
antibodi
binaxnow
influenza
b
rapid
test
howev
major
viru
strain
caus
influenza
outbreak
taiwan
type
type
fluivd
fail
mention
master
influenza
viru
strain
use
prepar
therefor
inappropri
master
influenza
viru
strain
use
fluivd
prepar
may
contribut
low
detect
sensit
moreov
studi
shown
analyt
sensit
directli
reflect
clinic
sensit
patient
specimen
analyt
sensit
influenza
detect
season
influenza
although
clinic
perform
poor
manufactur
j
u
r
n
l
f
f
n
r
u
g
n
l
follow
recommend
annual
pandem
influenza
viru
strain
use
prepar
fluivd
order
improv
qualiti
also
suggest
class
level
fluivd
taiwan
govern
regul
elev
govern
monitor
qualiti
ivd
use
lot
releas
system
furthermor
taiwan
fda
establish
refer
profici
panel
evalu
vitro
fluivd
near
futur
patient
suffer
respiratori
ill
cough
asthma
emphysema
usual
diagnos
acut
respiratori
tract
infect
virus
influenza
viru
coronaviru
respiratori
syncyti
viru
commonli
caus
respiratori
tract
infect
sever
studi
conduct
specif
test
realtim
polymeras
chain
reaction
analysi
differ
respiratorytractinfectionrel
virus
specif
fluivd
play
import
role
select
interact
influenza
b
virus
accord
epidemiolog
studi
hcov
caus
common
cold
adult
common
henc
use
common
determin
specif
fluivd
studi
result
show
fluivd
crossreact
suggest
good
specif
tabl
conclus
seven
domest
import
fluivd
collect
analyz
sensit
specif
analyt
sensit
fluivd
flu
b
ngml
ngml
ngml
respect
averag
sensit
fluivd
log
ae
ccid
ml
log
ae
ccid
ml
respect
product
crossreact
result
could
provid
inform
futur
policymak
strategi
prepared
season
pandem
influenza
tabl
e
specif
result
influenza
vitro
diagnost
devic
crossreact
specif
rate
human
j
u
r
n
l
f
f
n
r
u
g
n
l
